Introduction：Basic information about CAS 1610537-15-9|VT-464, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | VT-464 |
|---|
| CAS Number | 1610537-15-9 | Molecular Weight | 399.340 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 536.3±45.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H17F4N3O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 278.2±28.7 °C |
|---|
Names
| Name | VT-464 |
|---|
| Synonym | More Synonyms |
|---|
VT-464 BiologicalActivity
| Description | Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition. |
|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Cytochrome P450Research Areas >>Cancer |
|---|
| Target | IC50: 69 nM(h-CYP17 Lyase)[1]. |
|---|
| In Vitro | Seviteronel (VT-464), a non-steroidal small molecule inhibits androgen production without mineralocorticoid excess or cortisol depletion by selective inhibition of CYP17 17,20-lyase. We determined the impact of Seviteronel (VT-464) on tumor growth of a mCRPC xenograft, MDA-PCa-133, in vivo, and on androgen signaling in C4-2B prostate cancer cells in vitro[2]. |
|---|
| In Vivo | The MDA-PCa-133 xenograft is derived from a clinical CRPC bone metastasis. Subcutaneous MDA-PCa-133 tumor expresses PSA, full-length androgen receptor (AR) and AR-V7 isoform. We determined the effect of Seviteronel (VT-464) and AA on MDA-PCa-133 growing in tumor-bearing castrated male mice: randomization into three groups; oral treatment with vehicle only, VT-464, (100 mg/kg bid), or AA (100 mg/kg bid) for 25 days. Both Seviteronel (VT-464) and AA reduced tumor volume (>two fold compared to vehicle; p<0.05). These results indicate that selective Seviteronel (VT-464) CYP17 lyase inhibition is as effective as AA CYP17 inhibition in this model [2]. |
|---|
| References | [1]. Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. [2]. Sankar N. Maity, et al. Abstract 4772: Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 536.3±45.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H17F4N3O3 |
|---|
| Molecular Weight | 399.340 |
|---|
| Flash Point | 278.2±28.7 °C |
|---|
| Exact Mass | 399.120605 |
|---|
| LogP | 3.31 |
|---|
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
|---|
| Index of Refraction | 1.562 |
|---|
| InChIKey | ZBRAJOQFSNYJMF-SFHVURJKSA-N |
|---|
| SMILES | CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1 |
|---|
Synonyms
| seviteronel |
| MFCD28167778 |
| (1S)-1-[6,7-Bis(difluoromethoxy)-2-naphthyl]-2-methyl-1-(1H-1,2,3-triazol-4-yl)-1-propanol |
| 8S5OIN36X4 |
| 1H-1,2,3-Triazole-4-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- |
